GlassScriptPhysician profile
Jesse E Diaz Correa
NPI 1609242288
$5,094.36
in general payments reported to CMS, 2019-2025
22 companies · $741 in 2025
The $741 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $158 · 2021: $438 · 2022: $470 · 2023: $1,543 · 2024: $1,743 · 2025: $741.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,413 · Consulting Fee: $1,340 · Travel and Lodging: $1,175 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.43 |
| Consulting Fee | $1,340.00 |
| Travel and Lodging | $1,174.59 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,376.93 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,340.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $676.94 | 2020-2024 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.46 | 2024-2025 | Jardiance |
| Mallinckrodt Hospital Products INC. | $201.59 | 2023-2025 | Acthar |
| Vifor Pharma, INC. | $195.11 | 2022-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $154.00 | 2024 | Nxstage System One, Liberty Select Cycler |
| Bayer Puerto Rico INC. | $138.89 | 2024-2025 | Kerendia |
| Horizon Therapeutics Plc | $125.00 | 2022 | |
| Travere Therapeutics, INC. | $124.46 | 2025 | Filspari |
| Bayer Healthcare Pharmaceuticals INC. | $120.91 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $100.64 | 2021 | |
| Opko Pharmaceuticals, LLC | $67.53 | 2021 | |
| La Jolla Pharmaceutical Company | $47.06 | 2020 | |
| Ani Pharmaceuticals, INC. | $46.67 | 2024-2025 | Purified Cortrophin Gel |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $37.90 | 2024 | |
| Nxstage Medical, INC. | $30.38 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.13 | 2021 | |
| Lilly USA, LLC | $22.95 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $18.82 | 2020 | |
| Amgen INC. | $18.30 | 2025 | Krystexxa, Tavneos |
| Veloxis Pharmaceuticals, INC. | $15.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Diaz Correa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.